New Stada management appointed

The Supervisory Board of the German pharmaceutical group Stada, owner of Hemofarm, has appointed Claudio Albrecht as the new chairman of the Managing Board and Mark Keatley as the new Chief Financial Officer in the German concern.

Albrecht succeeds Engelbert Coster Tjeenk Willink, who has been temporary CEO since July 4, whereas Keatley will take over the position of the CFO from Bernhard Duttmann.

Albrecht used to be CEO and Chairman of generics manufacturer Actavis Group until its sale to Watson in 2012. Previously, he held the position of CEO at Ratiopharm Group. Albrecht started his career in the generics division of Sandoz, says the Stada press release.

Keatley served as Chief Financial Officer at Actavis Group until its sale. Prior to joining Actavis, he held the position of Chief Financial Officer at Famar, a European contract manufacturer for the healthcare industry.

Shortly before the appointment of the new Executive Board members, the Stada Supervisory Board elected Gunter von Au as its new Chairman in the course of its constituent meeting.

STADA Grupa

Hemofarm a.d. Vršac

Stada

Stada Managing Board

Hemofarm

Actavis Group

Watson

Famar

Ratiopharm Group

Claudio Albrecht

Mark Keatley

Bernhard Duttmann

Engelbert Coster Tjeenk Willink

Gunter von Au

Stada management